Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

BACKGROUND: Successful development of chimeric antigen receptor (CAR) T cell immunotherapy for children and adults with relapsed/refractory acute myeloid leukemia (AML) is highly desired given their poor clinical prognosis and frequent inability to achieve cure with conventional chemotherapy. Initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Haiying, Yang, Lila, Chukinas, John A, Shah, Nirali N, Tarun, Samiksha, Pouzolles, Marie, Chien, Christopher D, Niswander, Lisa M, Welch, Anthony R, Taylor, Naomi A, Tasian, Sarah K, Fry, Terry J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449984/
https://www.ncbi.nlm.nih.gov/pubmed/34531250
http://dx.doi.org/10.1136/jitc-2021-003149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449984/
https://www.ncbi.nlm.nih.gov/pubmed/34531250
http://dx.doi.org/10.1136/jitc-2021-003149

Ejemplares similares